SCHEMBL708886

SCHEMBL708886

CC(C)Oc1ccc(OCc2ccccc2)cc1-c1nc2cc(-c3cccc(F)c3)cnc2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GPR34 Q9UPC5 2/20 0.40
PDE4B Q07343 2/20 0.39
C5AR1 P21730 1/20 0.38
PDGFRB P09619 1/20 0.38
PDGFRA P16234 1/20 0.38
FFAR1 O14842 4/20 0.38
PPARD Q03181 3/20 0.38
WNT1 P04628 1/20 0.37
MAOB P27338 2/20 0.36
KIT P10721 1/20 0.36
MPO P05164 1/20 0.36
MCL1 Q07820 1/20 0.35
DHODH Q02127 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL711273 0.93 GPR34 (0.40) GPR34PDE4BC5AR1PDGFRBPDGFRA
SCHEMBL10206516 0.93 MCL1 (0.41) PDE4BPDGFRBPDGFRAPPARDMAOB
SCHEMBL711592 0.92 MCL1 (0.40) GPR34PDE4BPDGFRBPDGFRAMCL1
SCHEMBL720812 0.90 GPR34 (0.41) GPR34PPARDMAOB
SCHEMBL711177 0.88 PRMT5 (0.42) PDE4BPDGFRBPDGFRA
SCHEMBL710136 0.88 MAPT (0.43) PDE4BC5AR1PDGFRBPDGFRAMAOB
Trifluoroacetic Acid SCHEMBL711184 0.87 MCL1 (0.41) GPR34FFAR1PPARDMCL1DHODH
SCHEMBL713544 0.87 FFAR1 (0.40) PDGFRBPDGFRAFFAR1PPARDKIT
SCHEMBL719831 0.87 MAP4K4 (0.43) GPR34C5AR1MCL1DHODH
SCHEMBL712000 0.86 PRMT5 (0.38) PDE4BPDGFRBPDGFRAFFAR1PPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 EP claimed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US claimed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP claimed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO claimed
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK GPR34 2350/4885PDE4B 468/4885C5AR1 4609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.